Profile data is unavailable for this security.
About the company
Beam Therapeutics Inc. is a biotechnology company engaged in providing life-long cures to patients suffering from serious diseases. The Company operates a fully integrated platform for precision genetic medicines. Its base editing technology enables a differentiated class of precision genetic medicines that target a single base in the genome without making a double-stranded break in the deoxyribonucleic acid (DNA). The Company is advancing its base editing technology across three disease-area portfolios: hematology, immunology/oncology and genetic diseases. Its clinical-stage programs include BEAM-101, BEAM-201, BEAM-301 and BEAM-302. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy designed to offer a profile, incorporating base edits that are intended to mimic single nucleotide polymorphisms seen in individuals with hereditary persistence of fetal hemoglobin (HPFH). BEAM-201 is a development candidate comprised of T cells.
- Revenue in USD (TTM)76.70m
- Net income in USD-316.33m
- Incorporated2017
- Employees507.00
- LocationBeam Therapeutics Inc26 Landsdowne StCAMBRIDGE 02139-4216United StatesUSA
- Phone+1 (857) 327-8775
- Fax+1 (302) 655-5049
- Websitehttps://beamtx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BridgeBio Pharma Inc | 77.78m | -424.94m | 2.21bn | 392.00 | -- | -- | -- | 28.37 | -2.83 | -2.83 | 0.5215 | -7.64 | 0.1081 | -- | -- | 198,418.40 | -59.22 | -64.11 | -69.48 | -78.45 | 96.48 | 95.39 | -547.77 | -1,037.16 | -- | -- | 3.43 | -- | 11.38 | -- | 14.46 | -- | 68.60 | -- |
| Mirati Therapeutics Inc | 18.89m | -737.07m | 2.24bn | 587.00 | -- | 2.59 | -- | 118.44 | -12.95 | -12.95 | 0.3322 | 14.83 | 0.0154 | -- | 3.63 | 32,187.39 | -60.04 | -45.22 | -66.80 | -49.45 | 35.38 | -- | -3,901.06 | -1,744.74 | 7.51 | -- | 0.00 | -- | -82.75 | -- | -27.34 | -- | 126.71 | -- |
| Nuvalent Inc | 0.00 | -89.50m | 2.29bn | 70.00 | -- | 5.14 | -- | -- | -1.72 | -1.72 | 0.00 | 7.82 | 0.00 | -- | -- | 0.00 | -24.25 | -- | -25.11 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -76.65 | -- | -- | -- |
| Corcept Therapeutics Incorporated | 413.82m | 94.50m | 2.44bn | 299.00 | 29.44 | 4.90 | 25.60 | 5.89 | 0.8145 | 0.8145 | 3.57 | 4.90 | 0.7621 | 0.9612 | 13.86 | 1,384,027.00 | 17.40 | 23.08 | 19.90 | 25.75 | 98.67 | 98.39 | 22.84 | 29.15 | 6.69 | -- | 0.00 | 0.00 | 9.80 | 20.34 | -9.86 | -8.98 | -0.288 | -- |
| Beam Therapeutics Inc | 76.70m | -316.33m | 2.47bn | 507.00 | -- | 3.16 | -- | 32.17 | -4.46 | -4.46 | 1.08 | 10.23 | 0.0551 | -- | -- | 151,274.20 | -20.88 | -35.05 | -24.78 | -42.04 | -- | -- | -379.20 | -907.65 | -- | -- | 0.0032 | -- | 17.51 | -- | 22.00 | -- | 169.24 | -- |
| Akero Therapeutics Inc | 0.00 | -111.84m | 2.48bn | 41.00 | -- | 6.86 | -- | -- | -2.74 | -2.74 | 0.00 | 6.52 | 0.00 | -- | -- | 0.00 | -43.12 | -48.39 | -46.60 | -51.98 | -- | -- | -- | -- | -- | -96.76 | 0.0744 | -- | -- | -- | -11.17 | -- | -- | -- |
| Xenon Pharmaceuticals Inc | 668.00k | -147.38m | 2.55bn | 203.00 | -- | 3.68 | -- | 3,814.69 | -2.24 | -2.24 | 0.0103 | 10.89 | 0.001 | -- | 0.2597 | 3,290.64 | -23.07 | -21.60 | -23.64 | -23.05 | -- | -- | -22,070.36 | -462.39 | -- | -- | 0.00 | -- | -48.83 | 97.87 | -62.07 | -- | 55.83 | -- |
| Revance Therapeutics Inc | 156.64m | -351.87m | 2.56bn | 534.00 | -- | -- | -- | 16.34 | -4.61 | -4.61 | 2.06 | -0.3175 | 0.2638 | 3.12 | 15.79 | 293,324.00 | -59.27 | -54.14 | -67.78 | -60.87 | 61.73 | -- | -224.65 | -531.62 | 3.79 | -23.90 | 1.07 | -- | 70.40 | 247.40 | -26.70 | -- | 4.92 | -- |
| Insmed Incorporated | 257.47m | -546.68m | 2.56bn | 736.00 | -- | -- | -- | 9.96 | -4.26 | -4.26 | 2.02 | -0.3273 | 0.1928 | 0.8381 | 9.16 | 349,816.60 | -40.93 | -40.24 | -46.37 | -45.76 | 77.95 | 77.73 | -212.33 | -240.27 | 5.63 | -24.63 | 1.04 | -- | 30.19 | -- | -10.79 | -- | 26.91 | -- |
| Morphic Holding Inc | 68.95m | -63.69m | 2.58bn | 102.00 | -- | 5.32 | -- | 37.36 | -1.63 | -1.63 | 1.76 | 10.76 | 0.1644 | -- | 54.18 | 675,951.00 | -15.18 | -20.50 | -16.29 | -23.33 | -- | -- | -92.38 | -171.12 | -- | -- | 0.00 | -- | 257.72 | -- | 38.20 | -- | -17.33 | -- |
| ProKidney Corp | 0.00 | -50.21m | 2.58bn | 87.00 | -- | -- | -- | -- | -0.8159 | -0.8159 | 0.00 | -26.02 | 0.00 | -- | -- | 0.00 | -42.85 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0004 | -- | -- | -- | -95.90 | -- | -- | -- |
| Revolution Medicines Inc | 34.82m | -259.16m | 2.72bn | 259.00 | -- | 2.86 | -- | 78.20 | -3.04 | -3.04 | 0.406 | 8.96 | 0.0397 | -- | 7.43 | 141,528.50 | -29.52 | -30.02 | -31.53 | -33.44 | -- | -- | -744.36 | -355.93 | -- | -- | 0.00 | -- | 20.38 | -- | -32.93 | -- | 47.01 | -- |
| Immunovant Inc | 0.00 | -210.96m | 2.75bn | 164.00 | -- | 7.57 | -- | -- | -1.71 | -1.71 | 0.00 | 2.78 | 0.00 | -- | -- | 0.00 | -45.79 | -- | -50.62 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -34.60 | -- | -- | -- |
| Immunocore Holdings PLC - ADR | 204.65m | -51.58m | 2.77bn | 408.00 | -- | 8.19 | -- | 13.55 | -1.10 | -1.10 | 4.27 | 6.99 | 0.4654 | 0.5573 | 7.06 | 501,595.20 | -11.73 | -- | -14.54 | -- | 99.77 | -- | -25.21 | -- | 4.55 | -- | 0.1991 | -- | 441.99 | -- | 68.66 | -- | -- | -- |
| Azenta Inc | 594.21m | -25.38m | 2.78bn | 3.70k | -- | 1.03 | 78.06 | 4.68 | -0.3435 | 27.72 | 7.99 | 41.58 | 0.2309 | 3.07 | 3.29 | 185,691.30 | -0.9861 | 0.2068 | -1.11 | 0.2414 | 44.16 | 42.99 | -4.27 | 0.593 | 5.92 | -- | 0.0005 | 723.37 | 8.14 | 1.04 | 60.91 | -- | 43.07 | -24.21 |
Data as of May 26 2023. Currency figures normalised to Beam Therapeutics Inc's reporting currency: US Dollar USD
52.48%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| ARK Investment Management LLCas of 31 Mar 2023 | 8.57m | 11.84% |
| The Vanguard Group, Inc.as of 31 Mar 2023 | 6.22m | 8.59% |
| BlackRock Fund Advisorsas of 31 Mar 2023 | 4.42m | 6.11% |
| Temasek Holdings Pte Ltd. (Investment Management)as of 31 Mar 2023 | 4.09m | 5.66% |
| Fidelity Management & Research Co. LLCas of 31 Mar 2023 | 3.95m | 5.46% |
| Farallon Capital Management LLCas of 31 Mar 2023 | 3.43m | 4.74% |
| SSgA Funds Management, Inc.as of 31 Mar 2023 | 3.24m | 4.47% |
| Redmile Group LLCas of 31 Mar 2023 | 1.61m | 2.23% |
| Deep Track Capital LPas of 31 Mar 2023 | 1.25m | 1.73% |
| Geode Capital Management LLCas of 31 Mar 2023 | 1.20m | 1.66% |
More ▼
Data from 31 Mar 2023 - 31 Mar 2023Source: FactSet Research Systems Inc.
